Blueprint Medicines (NASDAQ:BPMC) Upgraded at StockNews.com

StockNews.com upgraded shares of Blueprint Medicines (NASDAQ:BPMC) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

A number of other research analysts also recently issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $133.00 price objective on shares of Blueprint Medicines in a research note on Thursday, February 13th. Wells Fargo & Company reduced their price target on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Piper Sandler lifted their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Stephens reissued an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $123.83.

Blueprint Medicines Stock Up 0.2 %

Blueprint Medicines stock opened at $92.48 on Friday. Blueprint Medicines has a fifty-two week low of $80.68 and a fifty-two week high of $121.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The firm’s 50-day simple moving average is $99.49 and its 200 day simple moving average is $94.44. The stock has a market cap of $5.91 billion, a PE ratio of -85.63 and a beta of 0.61.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Research analysts predict that Blueprint Medicines will post -1.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jeffrey W. Albers sold 15,161 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the transaction, the director now directly owns 152,396 shares in the company, valued at approximately $16,691,933.88. This represents a 9.05 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total transaction of $216,257.40. Following the transaction, the chief operating officer now directly owns 71,657 shares in the company, valued at $6,814,580.70. This trade represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 49,851 shares of company stock worth $4,984,696 in the last three months. 4.21% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Blueprint Medicines

A number of large investors have recently added to or reduced their stakes in BPMC. Pallas Capital Advisors LLC raised its stake in shares of Blueprint Medicines by 3.2% during the third quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock valued at $523,000 after acquiring an additional 176 shares during the last quarter. Torray Investment Partners LLC grew its position in shares of Blueprint Medicines by 1.1% in the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock worth $1,439,000 after buying an additional 186 shares during the last quarter. Sherbrooke Park Advisers LLC increased its stake in shares of Blueprint Medicines by 8.4% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 3,374 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 261 shares during the period. Franklin Resources Inc. raised its holdings in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock valued at $3,259,000 after acquiring an additional 265 shares in the last quarter. Finally, Summit Investment Advisors Inc. boosted its holdings in Blueprint Medicines by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company’s stock valued at $580,000 after acquiring an additional 283 shares in the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.